131 related articles for article (PubMed ID: 9203845)
21. Neuropeptide receptors in health and disease: the molecular basis for in vivo imaging.
Reubi JC
J Nucl Med; 1995 Oct; 36(10):1825-35. PubMed ID: 7562050
[No Abstract] [Full Text] [Related]
22. Modulation of pharmacokinetics of radioiodinated sugar-conjugated somatostatin analogues by variation of peptide net charge and carbohydration chemistry.
Schottelius M; Rau F; Reubi JC; Schwaiger M; Wester HJ
Bioconjug Chem; 2005; 16(2):429-37. PubMed ID: 15769098
[TBL] [Abstract][Full Text] [Related]
23. OctreoScan 111 for imaging of a somatostatin receptor-positive islet cell tumor in rat.
Bruns C; Stolz B; Albert R; Marbach P; Pless J
Horm Metab Res Suppl; 1993; 27():5-11. PubMed ID: 8392488
[TBL] [Abstract][Full Text] [Related]
24. [Significance of somatostatin receptors for diagnosis and therapy of endocrine pancreatic tumors].
Schusdziarra V
Z Gastroenterol; 1991 Jul; 29(7):363-4. PubMed ID: 1659049
[No Abstract] [Full Text] [Related]
25. Ten years of experience with MIBG applications and the potential of new radiolabeled peptides: a personal overview and concluding remarks.
Shapiro B
Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):150-5. PubMed ID: 9002776
[TBL] [Abstract][Full Text] [Related]
26. Somatostatin receptor scintigraphy before and after treatment with somatostatin analogues in patients with thyroid eye disease.
Krassas GE; Doumas A; Kaltsas T; Halkias A; Pontikides N
Thyroid; 1999 Jan; 9(1):47-52. PubMed ID: 10037076
[TBL] [Abstract][Full Text] [Related]
27. Vasoactive intestinal peptide-receptor imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
Virgolini I; Raderer M; Kurtaran A; Angelberger P; Banyai S; Yang Q; Li S; Banyai M; Pidlich J; Niederle B; Scheithauer W; Valent P
N Engl J Med; 1994 Oct; 331(17):1116-21. PubMed ID: 7935635
[TBL] [Abstract][Full Text] [Related]
28. Metastatic hormone-refractory prostatic adenocarcinoma expresses somatostatin receptors and is visualized in vivo by [111In]-labeled DTPA-D-[Phe1]-octreotide scintigraphy.
Nilsson S; Reubi JC; Kalkner KM; Laissue JA; Horisberger U; Olerud C; Westlin JE
Cancer Res; 1995 Dec; 55(23 Suppl):5805s-5810s. PubMed ID: 7493350
[TBL] [Abstract][Full Text] [Related]
29. Parallel in vivo and in vitro detection of functional somatostatin receptors in human endocrine pancreatic tumors: consequences with regard to diagnosis, localization, and therapy.
Lamberts SW; Hofland LJ; van Koetsveld PM; Reubi JC; Bruining HA; Bakker WH; Krenning EP
J Clin Endocrinol Metab; 1990 Sep; 71(3):566-74. PubMed ID: 2168430
[TBL] [Abstract][Full Text] [Related]
30. [Somatostatin receptor status in non-medullary thyroid carcinoma].
Görges R; Kahaly G; Müller-Brand J; Mäcke H; Walgenbach S; Bruns C; Andreas J; Brandt-Mainz K; Bockisch A
Nuklearmedizin; 1999; 38(1):15-23. PubMed ID: 9987777
[TBL] [Abstract][Full Text] [Related]
31. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
[TBL] [Abstract][Full Text] [Related]
32. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radioiodinated analog of somatostatin ([123I]SDZ 204-090).
Faglia G; Bazzoni N; Spada A; Arosio M; Ambrosi B; Spinelli F; Sara R; Bonino C; Lunghi F
J Clin Endocrinol Metab; 1991 Oct; 73(4):850-6. PubMed ID: 1653785
[TBL] [Abstract][Full Text] [Related]
33. Location of a VIPoma by iodine-123-vasoactive intestinal peptide scintigraphy.
Virgolini I; Kurtaran A; Leimer M; Kaserer K; Peck-Radosavljevic M; Angelberger P; Hübsch P; Dvorak M; Valent P; Niederle B
J Nucl Med; 1998 Sep; 39(9):1575-9. PubMed ID: 9744346
[TBL] [Abstract][Full Text] [Related]
34. The current status of somatostatin receptors in malignant melanoma.
Fletcher WS; Lum SS; Nance RW; Pommier RF; O'Dorisio MS
Yale J Biol Med; 1997; 70(5-6):561-3. PubMed ID: 9825484
[TBL] [Abstract][Full Text] [Related]
35. Candidates for peptide receptor radiotherapy today and in the future.
Reubi JC; Mäcke HR; Krenning EP
J Nucl Med; 2005 Jan; 46 Suppl 1():67S-75S. PubMed ID: 15653654
[TBL] [Abstract][Full Text] [Related]
36. Somatostatin receptor imaging and therapy of pancreatic endocrine tumors.
van Eijck CH; de Jong M; Breeman WA; Slooter GD; Marquet RL; Krenning EP
Ann Oncol; 1999; 10 Suppl 4():177-81. PubMed ID: 10436816
[TBL] [Abstract][Full Text] [Related]
37. Iodination of [Tyr11]somatostatin yields a super high affinity ligand for somatostatin receptors in GH4C1 pituitary cells.
Presky DH; Schonbrunn A
Mol Pharmacol; 1988 Nov; 34(5):651-8. PubMed ID: 2904115
[TBL] [Abstract][Full Text] [Related]
38. [111In-DPTA-D-Phe1]-octreotide scintigraphy in the management of patients with advanced renal cell carcinoma.
Edgren M; Westlin JE; Kälkner KM; Sundin A; Nilsson S
Cancer Biother Radiopharm; 1999 Feb; 14(1):59-64. PubMed ID: 10850288
[TBL] [Abstract][Full Text] [Related]
39. Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting.
Reubi C; Gugger M; Waser B
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):855-62. PubMed ID: 12111125
[TBL] [Abstract][Full Text] [Related]
40. Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with 111In-pentetreotide.
Limouris GS; Rassidakis A; Kondi-Paphiti A; Triantafyllou N; Manetou A; Giannakopoulos V; Toubanakis N; Psyhojios I; Stavraka A; Vlahos L
Anticancer Res; 1997; 17(3B):1593-7. PubMed ID: 9179200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]